兴齐眼药上半年净利润同比增长97.75% 拟10派7元（含税）

Core Viewpoint - The company, Xingqi Eye Medicine, reported significant growth in its financial performance for the first half of 2025, with a notable increase in revenue and net profit, reflecting its strong position in the ophthalmic pharmaceutical industry [1]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 1.163 billion yuan, representing a year-on-year growth of 30.38% [1]. - The net profit attributable to the parent company was 335 million yuan, marking a year-on-year increase of 97.75% [1]. - The basic earnings per share were reported at 1.36 yuan, and the company proposed a cash dividend of 7 yuan per 10 shares (tax included) [1]. Product Development and Pipeline - The company has a comprehensive product line covering various ophthalmic drug categories, including treatments for myopia, dry eye, eye infections, and glaucoma, among others [1]. - As of June 2025, the company has 60 approved ophthalmic drug registrations, with 38 products included in the medical insurance directory and 6 in the national essential drug list [2]. - The company is advancing several products in clinical trials, including Voriconazole eye drops, which have entered Phase II trials, and other products that are in various stages of clinical research [2][3]. Research and Development Capabilities - The company has established multiple technical platforms for ophthalmic drug development, including gel formulations and quality research, supported by a dedicated clinical medicine department and regulatory review department [2]. - The company has a strong track record in research and development, leveraging its industry foresight and accumulated experience to enhance its technical capabilities and product pipeline [2].